Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Credit Suisse Maintains Outperform on Corteva, Raises Price Target to $74

Credit Suisse Maintains Outperform on Corteva, Raises Price Target to $74

Credit Suisse analyst John Roberts maintains Corteva (NYSE:CTVA) with a Outperform and raises the price target from $72 to $74.

byBenzinga Newsdesk

November 4, 2022

1 minute read

Credit Suisse analyst John Roberts maintains Corteva (NYSE:CTVA) with a Outperform and raises the price target from $72 to $74.

Morgan Stanley Maintains Overweight on BeiGene, Lowers Price Target to $321

By Benzinga Newsdesk

February 28, 8:41 AM

Morgan Stanley analyst Matthew Harrison maintains BeiGene (NASDAQ:BGNE) with a Overweight and lowers the price target from $325 to $321.

BGNE

Atai Life Sciences Completes Phase 1 Clinical Study Of Oral Film DMT Formulation

By Lara Goldstein

October 3, 3:23 PM

Clinical-stage biopharma company atai Life Sciences (NASDAQ: ATAI) has completed its Phase 1 study evaluating proprietary oral transmucosal film (OTF) DMT formulation VLS-01 in 74 healthy participants.

ATAI

Apple’s Pivot-From-China Gamble Pays Off: 1 In 7 iPhones Now Made In India

By Shomik Sen Bhattacharjee

April 10, 5:01 AM

This story was first published on the Benzinga India portal.

AAPL

Analyst Ratings

Peeling Back The Layers: Exploring Allbirds Through Analyst Insights

By Benzinga Insights

May 9, 11:01 AM

Allbirds (NASDAQ:BIRD) has been analyzed by 5 analysts in the last three months, revealing a diverse range of…

BIRD

Credit Suisse Maintains Outperform on Corteva, Raises Price Target to $74

Related Posts

Morgan Stanley Maintains Overweight on BeiGene, Lowers Price Target to $321

Atai Life Sciences Completes Phase 1 Clinical Study Of Oral Film DMT Formulation

Apple’s Pivot-From-China Gamble Pays Off: 1 In 7 iPhones Now Made In India

Peeling Back The Layers: Exploring Allbirds Through Analyst Insights